Skip to content

The effect of semaglutide injection on gastric emptying time

The effect of semaglutide injection on gastric emptying time

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096141
Enrollment
Unknown
Registered
2025-01-19
Start date
2025-02-10
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric empty

Interventions

Test group:Fasting time

Sponsors

Department of Anesthesiology, Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Patients with type 2 diabetes aged 18 to 65 years, regardless of gender; 2) Patients who have received continuous semaglutide injections for 35 to 84 days prior to enrollment.

Exclusion criteria

Exclusion criteria: 1) Patients who have previously received semaglutide injections but have discontinued use or have been on the medication for less than 30 days prior to enrollment; 2) Patients with gastric outlet obstruction, gastric volvulus, significant/active esophageal/gastric/duodenal bleeding, achalasia, Zenker’s diverticulum, gastric cancer obstruction, or a history of upper gastrointestinal surgery; 3) Patients with multiple myeloma, systemic connective tissue diseases, or amyloidosis; 4) Traumatic state, anxiety and depression scale (The hospital anxiety and depression scale>=8 points), and severe chronic pain for more than 3 months (visual analogue score> in the last 3 months= 7 points) patients, long-term opioid use, drug addiction, alcohol abuse (consumption of more than 2 units of alcohol per day on average, 1 unit = 360 ml of beer or 45 ml of 40% liquor or 150 ml of wine); 5) Concomitant use/ingestion of medications known to affect gastric emptying (e.g., opioids, anticholinergics, tricyclic antidepressants, calcium channel blockers, progesterone, octreotide, proton pump inhibitors, H2-receptor antagonists, interferon, levodopa, sucralfate, aluminum hydroxide antacids, ß-adrenergic receptor agonists, glucagon, calcitonin, difenfluramine, diphenhydramine, etc., and GLP-1 receptor agonists other than semaglutide); 6) Pregnancy; 7) Patients who cannot lie on the right side.

Design outcomes

Primary

MeasureTime frame
Gastric emptying time in 90% of participants;

Secondary

MeasureTime frame
Gastric emptying time in 50% of participants;

Countries

China

Contacts

Public ContactLu Lin Qu Zongyang

Beijing Hospital

lulin8903@126.com+86 188 0140 4696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026